Ginger

Ginger inhibits thromboxane A2 synthesis (via COX-1 pathway) and reduces ADP-induced platelet aggregation. These antiplatelet effects are additive with clopidogrel, ticagrelor, and aspirin, potentially increasing bleeding risk. 6-Gingerol and 6-shogaol are the primary active antiplatelet constituents.

Use caution with high-dose ginger supplements (>2g/day) in patients on dual antiplatelet therapy. Monitor for signs of unusual bruising or bleeding. Advise discontinuation before invasive procedures.

Ginger has demonstrated hypoglycemic activity in clinical trials, attributed to inhibition of α-glucosidase, increased GLUT4 translocation, and enhancement of insulin sensitivity. Co-administration with antidiabetic drugs creates an additive risk of hypoglycemia, particularly with insulin and sulfonylureas.

Monitor blood glucose more frequently when initiating or increasing ginger supplementation alongside antidiabetic medications. Patients should be educated on signs and symptoms of hypoglycemia. Dose adjustment of antidiabetic agents may be required.

Phenytoin is primarily metabolized by CYP2C9 (and CYP2C19). Ginger inhibits CYP2C9 in vitro and in some animal models, potentially increasing phenytoin plasma concentrations. Phenytoin has an extremely narrow therapeutic index; even small increases in plasma levels can precipitate toxicity (nystagmus, ataxia, encephalopathy).

Avoid high-dose ginger supplements in patients on phenytoin. If patients wish to use ginger, monitor phenytoin serum levels and clinical signs of toxicity. Advise patient to report visual disturbances, unsteadiness, or confusion.

Ginger exerts antiplatelet activity (inhibition of thromboxane synthetase and COX-1 at high doses) and may inhibit CYP2C9 in vitro (IC50 ~10 μg/mL for powdered ginger), reducing S-warfarin metabolism. An animal study showed increased AUC of losartan (CYP2C9 substrate) with ginger co-administration. Pharmacodynamic bleeding risk is amplified when combined with warfarin.

Advise patients on warfarin to limit high-dose ginger supplementation (culinary amounts are generally safe). Monitor INR when initiating or stopping high-dose ginger. Discontinue at least 1-2 weeks before elective surgery.

Ginger has mild vasodilatory properties, including calcium channel blocking activity demonstrated in vitro. Concurrent use with antihypertensives may produce additive blood pressure lowering. Additionally, CYP2C9 inhibition may raise losartan AUC (an ARB) by reducing conversion to its active metabolite EXP3174, altering antihypertensive pharmacodynamics.

Culinary ginger use is unlikely to be clinically significant. High-dose ginger supplements should be used cautiously in patients on antihypertensives. Monitor blood pressure periodically and watch for symptoms of orthostatic hypotension.

In rat pharmacokinetic studies, ginger extract co-administration decreased oral cyclosporine bioavailability (AUC reduced approximately 50% at high ginger doses). The proposed mechanism involves P-gp induction or CYP3A4 induction in the gut wall, reducing first-pass absorption. Clinical significance in humans at culinary doses is uncertain but high-dose ginger supplementation in transplant patients warrants caution.

Transplant patients on cyclosporine or tacrolimus should be cautioned about high-dose ginger supplements. If used, monitor immunosuppressant trough levels. Standard culinary use is likely safe.

Ginger inhibits P-glycoprotein (P-gp) activity in vitro, which may increase intestinal absorption of P-gp substrate drugs including morphine. Clinical pharmacokinetic data suggest ginger potentiates morphine analgesic effects; one case report described morphine-like CNS depression enhancement. Co-administration with opioids may produce additive CNS depression and respiratory depression.

Monitor for enhanced opioid effects (sedation, respiratory depression, nausea) in patients combining ginger supplements with opioid analgesics. Consider reducing opioid dose and monitoring pain response carefully. Patients should be educated not to self-medicate with high-dose ginger supplements alongside prescribed opioids.

Ginger inhibits calcium channels in vascular smooth muscle via gingerol-mediated mechanisms, producing vasodilation and blood pressure lowering. Pharmacodynamic synergism with calcium channel blockers produces enhanced hypotensive effect. Additionally, in vitro CYP3A4 inhibition by ginger may reduce nifedipine and amlodipine metabolism, raising plasma drug concentrations.

Monitor blood pressure closely in patients combining ginger supplements with calcium channel blockers; symptomatic hypotension is possible. Advise patients to sit or stand slowly. High-dose ginger supplements carry greater risk than culinary ginger.

In vitro studies demonstrate ginger inhibits CYP2C9, which is the primary metabolic pathway for losartan (CYP2C9 substrate). An animal pharmacokinetic study confirmed ginger increased AUC of losartan significantly. CYP2C9 inhibition by ginger reduces the conversion of losartan to its active metabolite E-3174, potentially altering both the pharmacokinetics and pharmacodynamics of losartan therapy.

Monitor blood pressure response in patients on losartan or other CYP2C9-metabolized ARBs when combining with ginger supplements. INR monitoring is also indicated as CYP2C9 inhibition affects warfarin and multiple other drugs. High-dose ginger supplements are more concerning than culinary doses.